TrialBlood2024

Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume.

Frederick L Locke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.